Advanced Breast Cancer Clinical Trials in Shanghai
12 recruitingShanghai, China
Showing 1–12 of 12 trials
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled17 locationsNCT07347600
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled298 locationsNCT06380751
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Dalpiciclib in HR+/HER2- ABC
Advanced Breast Cancer
RenJi Hospital103 enrolled1 locationNCT06301438
Recruiting
Phase 1Phase 2
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Breast CancerAdvanced Breast CancerTreatment Side Effects+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05142475
Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin118 enrolled1 locationNCT07180264
Recruiting
Not Applicable
RC48-ADC in HER2-low Advanced Breast Cancer
Advanced Breast Cancer
RenJi Hospital36 enrolled1 locationNCT05831878
Recruiting
Phase 2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin123 enrolled1 locationNCT07180160
Recruiting
Phase 2
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin186 enrolled1 locationNCT07180082
Recruiting
Not Applicable
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin86 enrolled1 locationNCT05876065